Sector News

Novo Nordisk offers $3.1 billion for Belgian biotech group Ablynx

January 8, 2018
Life sciences

Ablynx already rejected an offer by the Danish group on Dec. 14 and Novo Nordisk said the new bid, made on Dec. 22, was some 14 percent higher. The Belgian company was not immediately available for comment on Monday.

“Novo Nordisk regrets that the board of directors of Ablynx has so far declined to engage in any discussions, despite the proposals which have been put forward,” it said in a statement.

The Danish company said it would pay 28.00 euros per share in cash for Ablynx and an additional 2.50 euros per share if certain conditions related to its research portfolio were met.

Ablynx’s shares have almost doubled in price in the past 12 months, buoyed by successful medical trial data. They closed at 21.20 euros on Friday.

Ablynx specializes in researching novel drugs based on nano-bodies found in the immune systems of llamas and alpacas, for which it partners with several of the world’s largest pharmaceutical firms.

Its products, which are all still undergoing medical trials, target many different diseases such as rheumatoid arthritis, psoriasis or cancer.

An acquisition would be the first by Novo Nordisk CEO Lars Fruergaard Jorgensen, who took over a year ago. He has said the firm needs external innovation to broaden its product line-up.

Novo Nordisk, the world’s biggest diabetes company, has sat out a rash of deal-making that has gripped the rest of the drugs industry in recent years. It has instead focused on its market-leading position making insulin and other diabetes treatments.

In March, the company approached Global Blood Therapeutics (GBT.O), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential takeover.

Tax breaks and other incentives have created a thriving biotech industry in Belgium, with many companies spun off from university projects now listed on the local stock exchange.

Last week, Japan’s Takeda (4502.T) bid 520 million euros for Belgian cell therapy group Tigenix. ($1 = 0.8322 euros)

By Robert-Jan Baratunek

Source: Reuters

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend